XBiotech (NASDAQ:XBIT) Sets New 12-Month High at $31.20

XBiotech Inc (NASDAQ:XBIT)’s share price reached a new 52-week high during trading on Tuesday . The stock traded as high as $31.20 and last traded at $25.19, with a volume of 136014 shares traded. The stock had previously closed at $18.62.

XBIT has been the topic of several recent research reports. Piper Jaffray Companies upped their price objective on XBiotech from $16.00 to $28.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 11th. ValuEngine lowered XBiotech from a “hold” rating to a “sell” rating in a research report on Wednesday, October 2nd. Zacks Investment Research upgraded XBiotech from a “hold” rating to a “buy” rating and set a $14.00 target price on the stock in a research report on Thursday, November 21st. Finally, BidaskClub lowered XBiotech from a “buy” rating to a “hold” rating in a research report on Wednesday, January 8th.

The business has a 50-day moving average of $17.01 and a 200-day moving average of $10.98. The stock has a market capitalization of $748.60 million, a price-to-earnings ratio of -43.14 and a beta of 0.64.

XBiotech (NASDAQ:XBIT) last issued its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.15). As a group, analysts expect that XBiotech Inc will post -0.62 EPS for the current year.

A number of institutional investors have recently made changes to their positions in the stock. JPMorgan Chase & Co. acquired a new stake in shares of XBiotech in the second quarter valued at about $34,000. A.R.T. Advisors LLC acquired a new stake in shares of XBiotech during the 2nd quarter worth approximately $101,000. Squarepoint Ops LLC acquired a new stake in shares of XBiotech during the 3rd quarter worth approximately $135,000. Citadel Advisors LLC acquired a new stake in shares of XBiotech during the 2nd quarter worth approximately $146,000. Finally, Barclays PLC raised its position in shares of XBiotech by 12.2% during the 3rd quarter. Barclays PLC now owns 15,905 shares of the biopharmaceutical company’s stock worth $166,000 after purchasing an additional 1,728 shares during the period. Institutional investors own 11.96% of the company’s stock.

About XBiotech (NASDAQ:XBIT)

XBiotech Inc, a pre-market biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The company's lead product is bermekimab, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer.

Featured Story: Purposes and Functions of the Federal Reserve

Receive News & Ratings for XBiotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XBiotech and related companies with MarketBeat.com's FREE daily email newsletter.